Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P689 | DOI: 10.1530/endoabs.35.P689

ECE2014 Poster Presentations Male reproduction (25 abstracts)

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume: study during up to 6 years on hypogonadic patients

Matei Pisoschi 1 , Mara Carsote 2 , Catalina Poiana 2 , Cristina Daniela Staicu 3 & Dan Peretianu 3


1Panduri-Burghele Hospital, Bucharest-Bucuresti, Romania; 2Institue of Endocrinology, Bucharest-Bucuresti, Romania; 3SCM Povernei, Bucharest-Bucuresti, Romania.


Aim: Re-analyzing the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.

Materials & methods: (A) Patients: at onset 191 men with hypogonadism (median age: 64 years). (B) Distribution: by decade. (C) TUD (NebidoR-Bayer-Schering) 1000 mg was injected one per 3 months i.m. (D) Prostate volume (PV) by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm3), Aloka 550. (E). Time of analysis: before starting testosterone (T0), after ½ month (T1), 3 (T2), 6 months (T3), 1 (T4), 2 (T5), 3 (T6), 4 (T7), 5 (T8), 6 years (T9). (F). Maximum increment percent from T0 was noted Δ M %. Average increment was noted Δ A %. G. Statistical analysis: Student’s t-test.

Results: i) All average prostatic volume for decade will be presented. ii) PV at T0 increases with age, from 17.33 (19–29 years) to 47.41 (80–89 years), P=0.0007. iii) Inside a specific decade no significant increased in PV was registered (all P>0.05), excepted 80–89 decade (at 3 and 4 years: P< 0.002). iv) In some patients, especially from 50 to 79 years, TUD could decrease slightly prostatic volume. v) When withdrawing the treatment, PV increased. vi) Five patients 78–89 years died after 1 year after withdrawing the treatment.

Conclusions: Considering the risk for prostate (in elderly), testosterone undecanoat 1000 mg depot injectable is a safe treatment, even after 3–6 years of administration. Precautions should be accorded to men over 80 years old, after the third administration. Further observation needed.

Article tools

My recent searches

No recent searches.